Twist Bioscience Corporation reports results for the quarter ended September 30 - Earnings Summary

• Twist Bioscience Corporation reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of eleven analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -45 cents to -28 cents per share.

• Revenue rose 27.9% to $126.64 million from a year ago; analysts expected $123.09 million.

• Twist Bioscience Corporation's reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $20.62 million.

• Twist Bioscience Corporation shares had fallen by 36.6% this quarter and gained 286.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Twist Bioscience Corporation is $150.00, about 18.3% above its last closing price of $122.59

This summary was machine generated from LSEG data November 12 at 05:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)